Role of PET/CT in initial evaluation of lymphoma patients

Springer Science and Business Media LLC - Tập 52 - Trang 1-9 - 2021
Manar Mohamed Naguib1, Samer Malak Botros1, Amir Louis Louka1, Rasha S. Hussein1
1Radiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Tóm tắt

Accurate radiologic assessment of treatment response in lymphoma patients is important to evaluate the effectiveness of treatment and consequently predict the relapse; the value of PET/CT for post-treatment prognosis prediction has been recently investigated. The aim of this study is to highlight the prognostic value of PET-CT metabolic volumetric parameters in the evaluation of lymphoma patients. Among the included 40 patients, post-treatment SUV, MTV, and TLG were significantly lower in a responsive group than the non-responsive group. % changes of all quantitative PET/CT parameters were significantly higher in the responsive group than the non-responsive group. This study suggests that pre-treatment PET/CT quantitative measures (except baseline SUVmax) are not conclusive in the prediction of patient response to treatment; however, the ΔSUVmax, ΔMTV, and ΔTLG% from the baseline to the end of therapy could be used in predicting patient response to treatment, determining patient prognosis, and suggesting the relapse.

Tài liệu tham khảo

Buchpiguel CA (2011) Current status of PET/CT in the diagnosis and follow up of lymphomas. Rev Bras Hematol Hemoter 33(2):140–147

Kwee TC, Kwee RM, Nievelstein RJ (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111:504–516

Burggraaff CN, De Jong A, Hoekstra OS et al (2019) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur JNucl Med Mol Imaging 46:65–79

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin 32(27):3059–3068

Adams HJ, Nievelstein RA, Kwee TC (2015) Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol 170(2):185–191

Adams HJ, Nievelstein RA, Kwee TC (2015) Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis. Br J Haematol 170(3):356–366

Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103(7):2474–2479

Vaidya R, Witzig TE (2014) Prognostic factors for diffuse large B-cell lymphoma in the R(X) CHOP era. Ann Oncol 25(11):2124–2133

Xie M, Zhai W, Cheng S et al (2016) Predictive value of FDG PET /CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology 21(2):99–105

Kanoun S, Tal I, Berriolo-Riedinger A et al (2018) Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma. PLoS ONE 10:e0140830

Jh O, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 280:576–584

Khong PL, Huang B, Lee EY et al (2014) Mid treatment FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med 55:911–916

Metser U, Hussey D, Murphy G (2014) Impact of (18) F-FDG PET/CT on the staging and management of follicular lymphoma. Br J Radiol 87(1042):20140360

Persijn V, Meerten V, Gelderblom H et al (2010) RECIST revised implications for the radiologist: a review article on the modified RECIST guideline. Eur Radiol 20:1456–1467

Cheson BD, Kostakoglu L (2017) FDG-PET for early response assessment in lymphomas Part 2–diffuse large B-cell lymphoma: use of quantitative PET evaluation. Oncology (Williston Park) 31:71–76

Liao CC, Qin YY, Tan XH et al (2017) Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma. Oncol Targets Ther 10:5727–5738

Freudenberg LS, Anotch G, Schütt P et al (2004) FDG-PET/CT in restaging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31:325–329

Chang Y, Fu X, Sun Z et al (2017) Utility of baseline, interim and end-of-treatment (18) F-FDG PET/CT in extra-nodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase. Sci Rep 7:41057

Cheson BD, Kostakoglu L (2017) FDG-PET for early response assessment in lymphomas Part 1—Hodgkin lymphoma. Oncology (Williston Park) 31:45–49

Huang H, Xiao F, Han X et al (2016) Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma. Nucl Med Commun 37(7):689–698

Ngeow JY, Quek RH, Ng DC et al (2009) High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 20:1543–1547

Albano D, Mazzoletti A, Spallino M et al (2020) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol 99:1321–1330

Akhtari M, Milgrom SA, Pinnix CC et al (2018) Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131(1):84–94

Mettler J, Müller H, Voltin CA et al (2019) Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med 60:207–211

Zanoni L, Cerci JJ, Fanti S (2011) Use of PET/CT to evaluate response to therapy in lymphoma. Q J Nucl Med Mol Imaging 55:633–647

Okada M, Sato N, Ishii K et al (2010) FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the post therapy evaluation of malignant lymphoma. Radiographics 30:939–957

Itti E, Lin C, Dupuis J et al (2009) Prognostic value of 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50:527–533

Zhou Y, Zhao Z, Li J et al (2019) Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma. Cancer Manage Res 11:6871–6885

Kim HJ, Lee R, Choi H et al (2018) Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma. Nucl Med Mol Imaging 52(5):342–349

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 52

1-9

Thông tin tác giả